Novozymes and
Chr. Hansen to combine

PLEASE READ THIS NOTICE CAREFULLY BEFORE ANSWERING “YES” OR “NO”AT THE BOTTOM OF THE PAGE – THE NOTICE APPLIES TO ALL VISITORS OF THIS WEBSITE, WWW.POWER-WITH-BIOLOGY.COM (the “Website”). DUE TO LEGAL RESTRICTIONS, THE INFORMATION ON THIS WEBSITE IS NOT DIRECTED TO, OR ACCESSIBLE FOR, CERTAIN PERSONS.

DEPENDING ON WHO YOU ARE AND WHERE YOU LIVE, IT MAY AFFECT YOUR RIGHTS. PLEASE NOTE THAT THIS NOTICE AND THE INFORMATION CONTAINED IN IT MAY BE ALTERED OR UPDATED FROM TIME TO TIME AND SHOULD BE READ IN FULL EACH TIME YOU VISIT THE SITE. IN ADDITION, THE CONTENTS OF THIS WEBSITE MAY BE AMENDED AT ANY TIME IN WHOLE OR IN PART AT THE SOLE DISCRETION OF NOVOZYMES A/S, KROGSHOEJVEJ 36, DK-2880 BAGSVAERD, DENMARK, COMPANY REG. NO. 10007127 ("NOVOZYMES").

ACCESS TO THE MATERIALS CONTAINED ON THIS WEBSITE MAY BE RESTRICTED UNDER THE SECURITIES LAWS IN CERTAIN JURISDICTIONS.

THIS NOTICE REQUIRES YOU TO CONFIRM CERTAIN MATTERS (INCLUDING THAT YOU ARE NOT RESIDENT IN SUCH JURISDICTION) BEFORE YOU MAY OBTAIN ACCESS TO THE INFORMATION ON THE WEBSITE. IF YOU ARE UNABLE, OR HAVE ANY DOUBT WHETHER YOU ARE ABLE, TO PROVIDE THE NECESSARY CONFIRMATION, THEN YOU SHOULD PRESS 'NO' AND YOU WILL NOT BE ABLE TO VIEW INFORMATION ON THE WEBSITE.

The information contained on this Website is not intended for, and must not be accessed by, or distributed or disseminated, directly or indirectly, in whole or in part, to persons resident or physically present in the United States of America (including its territories and possessions, any state of the United States and the District of Columbia, the "United States") (subject to certain exceptions), Canada, South Africa and Japan, or any jurisdiction where doing so might constitute a violation of the local securities laws or regulations of such jurisdiction. Further, the information contained on this Website does not constitute an offer to sell or the solicitation of an offer to buy or acquire, any shares or other securities of Novozymes or Chr. Hansen Holding A/S, Boege Allé 10-12, DK-2970 Hoersholm, Denmark, company reg. no. 28318677 (“Chr. Hansen”).

None of the shares referred to on this Website (the "Shares") have been or will be registered under the U.S. Securities Act of 1933, as emended (the “Securities Act”) and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. There is no intention to register any Shares referred to herein in the United States or to make a public offering of Shares in the United States.

Access to the information and documents contained on the Website may be illegal in certain jurisdictions, and only certain categories of persons may be authorized to access such information and documents. All persons residing in jurisdictions other than Denmark or Australia who wish to have access to the documents contained on this Website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this Website or require registration or approval for any acquisition of securities by them. No such registration or approval has been obtained outside of Denmark or Australia. Novozymes assumes no responsibility if there is a violation of applicable law and regulations by any person.

The contents of this Website are not to be incorporated into, or construed to form part of, any of the documents included herein, unless specifically stated in such documents. Except as otherwise explicitly stated herein as applicable to them, no information included on this Website should be used by investors in forming their investment decision.

The use of this Website is subject to Danish law and any disputes arising out of or regarding this Website is subject to Danish law and the exclusive jurisdictions of the Danish courts.

I therefore certify that

I am:

resident in Denmark; OR
resident in Australia; OR
a “qualified institutional buyer” in the United States as such term is defined in Rule 144A of the Securities Act; OR
an institutional investor neither located or resident in the United States, Canada, South Africa, Japan nor any jurisdiction in which it would be unlawful to access any prospectus, exemption document or other offer materials published by Novozymes in connection with the proposed transaction.

AND

I have read, understand and agree to comply with all of the restrictions set forth above in this notice.

Novozymes and Chr. Hansen to combine

Conference call

Key documents

Exemption document and related documents

Exemption document (for other jurisdictions than Australia)

Exemption document for shareholders of Chr. Hansen Holding A/S residing in Australia

Retail brochure (in Danish only)

Merger documents

Merger plan

Merger statement

Tax-exempt merger ruling

Auditor documents

Valuer’s report on the merger plan

Valuer’s report on the creditors’ position after merger

Extraordinary shareholder’s meeting March 30, 2023

Notice convening the extraordinary general meeting

Live streaming of extraordinary shareholders’ meeting

Live streaming of extraordinary shareholders’ meeting (in Danish)

Resolutions from extraordinary shareholders’ meeting

Minutes from extraordinary shareholders’ meeting

Announcements

Update on merger EC offered remedy proposal

Executive Leadership Team and organizational structure announced for the future combined company of Novozymes and Chr. Hansen

Stock exchange announcement regarding approval of combination by Novozymes shareholders

Investor news on the approval of combination by the Novozymes shareholders and Chr. Hansen shareholders

Press release on the approval of combination by the Novozymes shareholders and Chr. Hansen shareholders

Investor news on U.S. antitrust regulation

Investor news on Chinese merger approval

Stock exchange announcement regarding exemption document

Stock exchange announcement regarding proposed merger

Press release regarding proposed merger

Presentation

Investor presentation (December 12, 2022)

Conference call (December 12, 2022)

Other documents

Presentation of the Executive Leadership Team of the future combined company

Draft articles of association for Novozymes after completion of the Merger

Revised remuneration policy

Novozymes Remuneration Report 2022

Novozymes Articles of Association (March 30, 2023)

Novozymes annual reports

The Novozymes Annual Report 2022

The Novozymes Annual Report 2021

The Novozymes Annual Report 2020

The Novozymes Annual Report 2019

Chr. Hansen annual reports

The Chr. Hansen Annual Report 2021/2022

The Chr. Hansen Annual Report 2020/2021

The Chr. Hansen Annual Report 2019/2020

FAQ

Factsheet

Contacts

Investor relations

Tobias Cornelius Björklund

Media relations

Lina Danstrup

Restricted access

Novozymes and Chr. Hansen to combine

Disclaimer

Novozymes and
Chr. Hansen to combine

Novozymes and
Chr. Hansen to combine